Spots Global Cancer Trial Database for andecaliximab
Every month we try and update this database with for andecaliximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | NCT01803282 | Pancreatic Canc... Non-small Cell ... Esophagogastric... Colorectal Canc... Breast Cancer | Andecaliximab Gemcitabine Nab-paclitaxel Carboplatin Pemetrexed Leucovorin Oxaliplatin 5-FU Bevacizumab Irinotecan Paclitaxel | 18 Years - | Gilead Sciences | |
| Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02545504 | Gastric Adenoca... | Andecaliximab Placebo Leucovorin 5-fluorouracil Oxaliplatin | 18 Years - | Gilead Sciences | |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02862535 | Gastric Adenoca... | Andecaliximab S-1 Cisplatin Oxaliplatin Nivolumab | 20 Years - | Gilead Sciences | |
| Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02545504 | Gastric Adenoca... | Andecaliximab Placebo Leucovorin 5-fluorouracil Oxaliplatin | 18 Years - | Gilead Sciences | |
| Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis | NCT02862574 | Rheumatoid Arth... | Andecaliximab Placebo Methotrexate TNF Inhibitor | 18 Years - 80 Years | Gilead Sciences | |
| Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02545504 | Gastric Adenoca... | Andecaliximab Placebo Leucovorin 5-fluorouracil Oxaliplatin | 18 Years - | Gilead Sciences | |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02862535 | Gastric Adenoca... | Andecaliximab S-1 Cisplatin Oxaliplatin Nivolumab | 20 Years - | Gilead Sciences | |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02862535 | Gastric Adenoca... | Andecaliximab S-1 Cisplatin Oxaliplatin Nivolumab | 20 Years - | Gilead Sciences | |
| Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02545504 | Gastric Adenoca... | Andecaliximab Placebo Leucovorin 5-fluorouracil Oxaliplatin | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
